Table 3 Univariable and multivariable Cox proportional hazard regression analyses of event-free survival
Factor | Univariable analysis | P | Multivariable analysis | P |
|---|---|---|---|---|
HR (95%CI) | HR (95% CI) | |||
Gender | ||||
Male | Reference | |||
Female | 1.107 (0.614–1.993) | 0.735 | ||
Age at diagnosis | ||||
< 30y | Reference | |||
≥ 30 y | 1.410(0.820–2.426) | 0.215 | ||
Primary site | ||||
Extremity | Reference | |||
Trunk | 0.874 (0.500–1.526) | 0.635 | ||
Tumor origin | ||||
Skeletal | Reference | |||
Extraskeletal | 0.771 (0.418–1.421) | 0.404 | ||
Stage | ||||
Localized | Reference | Reference | ||
Metastatic | 1.644 (0.958–2.282) | 0.071 | 1.743 (1.012–3.002) | 0.045 |
Diameter of primary tumor | ||||
< 8 cm | Reference | |||
≥ 8 cm | 0.800 (0.458–1.398) | 0.434 | ||
Local therapy | ||||
Surgery | Reference | |||
Radiotherapy | 1.504 (0.733–3.087) | 0.266 | ||
Surgery + radiotherapy | 1.494 (0.806–2.771) | 0.202 | ||
Time to local therapy | 0.899 (0.732–1.104) | 0.309 | ||
Number of chemotherapy cycles | ||||
< 12 | Reference | Reference | 0.037 | |
≥ 12 | 0.592 (0.344–1.017) | 0.058 | 0.558 (0.323–0.965) | |
Frequency of chemotherapy delays | ||||
≥ 25% | Reference | |||
< 25% | 0.739 (0.380–1.439) | 0.374 | ||
Grade 3–4 chemotherapy toxicity | ||||
YES | Reference | |||
NO | 0.382(0.053–2.778) | 0.342 | ||
Administration of dexrazoxane | ||||
YES | Reference | |||
NO | 1.057(0.616–1.814) | 0.840 | ||